AU2016354478B2 - Protease-activated receptor-2 modulators - Google Patents

Protease-activated receptor-2 modulators Download PDF

Info

Publication number
AU2016354478B2
AU2016354478B2 AU2016354478A AU2016354478A AU2016354478B2 AU 2016354478 B2 AU2016354478 B2 AU 2016354478B2 AU 2016354478 A AU2016354478 A AU 2016354478A AU 2016354478 A AU2016354478 A AU 2016354478A AU 2016354478 B2 AU2016354478 B2 AU 2016354478B2
Authority
AU
Australia
Prior art keywords
peptide
amino acid
certain embodiments
xaa
absent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016354478A
Other languages
English (en)
Other versions
AU2016354478A1 (en
Inventor
Richard Looby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oasis Pharmaceuticals LLC
Original Assignee
Oasis Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oasis Pharmaceuticals LLC filed Critical Oasis Pharmaceuticals LLC
Publication of AU2016354478A1 publication Critical patent/AU2016354478A1/en
Application granted granted Critical
Publication of AU2016354478B2 publication Critical patent/AU2016354478B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2016354478A 2015-11-13 2016-11-11 Protease-activated receptor-2 modulators Active AU2016354478B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255334P 2015-11-13 2015-11-13
US62/255,334 2015-11-13
PCT/US2016/061489 WO2017083618A1 (en) 2015-11-13 2016-11-11 Protease-activated receptor-2 modulators

Publications (2)

Publication Number Publication Date
AU2016354478A1 AU2016354478A1 (en) 2018-05-31
AU2016354478B2 true AU2016354478B2 (en) 2021-07-22

Family

ID=57394682

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016354478A Active AU2016354478B2 (en) 2015-11-13 2016-11-11 Protease-activated receptor-2 modulators

Country Status (6)

Country Link
US (2) US11091533B2 (enExample)
EP (1) EP3374386B1 (enExample)
JP (3) JP7621728B2 (enExample)
AU (1) AU2016354478B2 (enExample)
ES (1) ES2984663T3 (enExample)
WO (1) WO2017083618A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination
AU2016354478B2 (en) 2015-11-13 2021-07-22 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators
WO2017194716A1 (en) * 2016-05-12 2017-11-16 Astrazeneca Ab Inhibitors of protease-activated receptor-2
AU2019310039A1 (en) * 2018-07-23 2021-02-18 Enclear Therapies, Inc. Methods of treating neurological disorders
KR20220011123A (ko) 2019-04-11 2022-01-27 엔클리어 테라피스, 인크. 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템
EP4055032A1 (en) * 2019-11-07 2022-09-14 The Board Of Trustees Of The University Of Illinois Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation
EP4090372A4 (en) * 2020-01-14 2023-10-18 Mayo Foundation for Medical Education and Research Targeting par1 and par2 to regulate lipid and cholesterol abundance
EP4221801A4 (en) 2020-09-29 2024-11-06 Enclear Therapies, Inc. METHOD AND SYSTEM FOR MANAGING SUBARACHNOID FLUID

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010021822A2 (en) * 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
WO2012139137A2 (en) * 2011-04-08 2012-10-11 Tufts Medical Center, Inc. Pepducin design and use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
US5874400A (en) * 1993-07-26 1999-02-23 Cor Therapeutics Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor
EP0835928A1 (en) 1996-10-11 1998-04-15 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Helicobacter pylori live vaccine
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6815200B1 (en) 1998-02-17 2004-11-09 The Uab Research Foundation Modified adenovirus containing a fiber replacement protein
US6503511B1 (en) 1998-04-07 2003-01-07 Medimmune, Inc. Derivatives of choline binding proteins for vaccines
US6562958B1 (en) 1998-06-09 2003-05-13 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics
WO2000034469A1 (en) 1998-12-11 2000-06-15 The Research Foundation Of State University Of New York At Albany Compositions and methods for altering cell migration
US6703491B1 (en) 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7696168B2 (en) 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
CA2406839C (en) 2000-04-21 2013-06-11 Athan Kuliopulos G-protein coupled receptor (gpcr) agonists and antagonists and methods of activating and inhibiting gpcr using the same
US6773893B1 (en) 2000-04-28 2004-08-10 The Trustees Of Columbia University In The City Of New York Human ABC1 promoter and assays based thereon
US7834146B2 (en) 2000-05-08 2010-11-16 Monsanto Technology Llc Recombinant polypeptides associated with plants
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
ES2565578T3 (es) 2002-08-02 2016-04-05 South Alabama Medical Science Foundation Vacunas contra el cáncer que contienen epítopos de antígeno oncofetal
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7189691B2 (en) 2004-04-01 2007-03-13 The Administrators Of The Tulane Educational Fund Methods and compositions for treating leukemia
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
US7319142B1 (en) 2004-08-31 2008-01-15 Monsanto Technology Llc Nucleotide and amino acid sequences from Xenorhabdus and uses thereof
CN101094866A (zh) 2004-11-04 2007-12-26 新英格兰医疗中心医院有限公司 G蛋白耦合受体激动剂和拮抗剂及其使用方法
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
US7739055B2 (en) 2005-11-17 2010-06-15 Massachusetts Institute Of Technology Methods and systems for generating and evaluating peptides
AU2007218045B2 (en) 2006-02-20 2011-11-10 Phylogica Limited Method of constructing and screening libraries of peptide structures
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
JP4400668B2 (ja) 2007-11-01 2010-01-20 株式会社豊田中央研究所 微小物体が固定化された固相体の製造方法及びその利用
US9029636B2 (en) 2008-02-05 2015-05-12 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
BRPI0921650A2 (pt) 2008-11-04 2019-07-30 Anchor Therapeutics Inc compostos receptores de cxcr4
BRPI0921815A2 (pt) 2008-11-04 2018-10-09 Anchor Therapeutics Inc compostos receptores de apj
US20110039763A1 (en) 2009-01-06 2011-02-17 C3 Jian, Inc. Targeted antimicrobial moieties
US9012723B2 (en) 2009-01-16 2015-04-21 Monsanto Technology Llc Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits
US8389679B2 (en) 2009-02-05 2013-03-05 The Regents Of The University Of California Targeted antimicrobial moieties
JO3246B1 (ar) 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9091651B2 (en) * 2011-12-21 2015-07-28 Integrated Diagnostics, Inc. Selected reaction monitoring assays
AU2016354478B2 (en) 2015-11-13 2021-07-22 Oasis Pharmaceuticals, LLC Protease-activated receptor-2 modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010021822A2 (en) * 2008-07-30 2010-02-25 The Regents Of The University Of California Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
WO2012139137A2 (en) * 2011-04-08 2012-10-11 Tufts Medical Center, Inc. Pepducin design and use

Also Published As

Publication number Publication date
US20210061883A1 (en) 2021-03-04
JP2022179508A (ja) 2022-12-02
JP2018537529A (ja) 2018-12-20
US11732027B2 (en) 2023-08-22
AU2016354478A1 (en) 2018-05-31
EP3374386C0 (en) 2024-05-29
EP3374386A1 (en) 2018-09-19
US11091533B2 (en) 2021-08-17
EP3374386B1 (en) 2024-05-29
ES2984663T3 (es) 2024-10-30
JP7621728B2 (ja) 2025-01-27
WO2017083618A1 (en) 2017-05-18
CA3005029A1 (en) 2017-05-18
US20170137492A1 (en) 2017-05-18
JP2025036429A (ja) 2025-03-14

Similar Documents

Publication Publication Date Title
US11732027B2 (en) Protease-activated receptor-2 modulators
KR102068370B1 (ko) 심부전의 치료를 위한 합성 아펠린 모방체
TWI750725B (zh) 新穎脂肪酸及其於共軛至生物分子之用途
EP3891174A1 (en) Modified gip peptide analogues
EP2697386B1 (en) Pepducin design and use
AU2019218786A1 (en) Cell-permeable stapled peptide modules for cellular delivery
JP2009508885A (ja) 治療的介入のためのｙ４選択性レセプターアゴニスト
US11572399B2 (en) Long-acting GIP peptide analogues
CN100425282C (zh) 用于治疗性干预的y2/y4选择性受体激动剂
EP3189072B1 (en) Gip peptide analogues
CA3005029C (en) Protease-activated receptor-2 modulators
JP2023508256A (ja) 血管新生および血管機能を阻害するオリゴペプチド

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)